AIR Awarded Federal Contract for Gene Therapy Access Program
![AIR Awarded Federal Contract for Gene Therapy Access Program](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
American Institutes for Research Awarded Federal Contract
The American Institutes for Research (AIR) has been awarded a federal contract to assist in implementing and monitoring a pioneering program aimed at increasing access to transformative cell and gene therapy (CGT) treatments for Medicaid recipients. This contract, amounting to $28 million, is granted by the Center for Medicare and Medicaid Innovation (CMMI) under the Centers for Medicare and Medicaid Services (CMS). AIR experts will support the execution of the CGT Access Model.
Focus on Transformative Cell and Gene Therapies
CGTs represent an emerging class of one-time medications designed to address previously hard-to-treat diseases. The CGT Access Model is designed to assess the effectiveness of a collaborative approach between CMS and states in negotiating and managing outcomes-based agreements (OBAs), with the goal of enhancing access and health results for individuals on Medicaid, minimizing healthcare expenses, and promoting health equity.
Initial Focus on Sickle Cell Disease
The model will initially target Sickle Cell Disease (SCD), a hereditary blood disorder that impacts over 100,000 individuals in the United States, predominantly affecting Black populations. Patients with SCD typically have a life expectancy that is over two decades shorter than the national average and often endure severe pain episodes, resulting in frequent hospital admissions.
AIR's Role and Responsibilities
Through this contract, AIR will play a crucial role in the implementation, monitoring, and data analysis associated with the program. AIR is recognized for its depth of experience in CMMI model implementation and is dedicated to promoting health equity across its initiatives.
Key Responsibilities Include:
- Monitoring the implementation and outcomes of the CGT Access Model;
- Developing and executing an extensive data collection and analysis strategy to evaluate health outcomes and financial metrics;
- Presenting findings at conferences to share knowledge and encourage innovation.
Collaboration with Esteemed Partners
Daniela Zapata, a principal researcher at AIR, is appointed as the project director for this initiative. AIR collaborates with Deloitte and Wally Smith, the Florence Neal Cooper Smith Professor of Sickle Cell Disease and Director of the Adult Sickle Cell Program at Virginia Commonwealth University, on this project.
Potential Impact on Healthcare
“The Cell and Gene Therapy Access Model holds the promise of making groundbreaking treatments more accessible to those in need while also reducing long-term healthcare costs,” commented Timothy Hill, senior vice president at AIR and leader of the institution’s Health Division. “We are eager to partner with CMS and others to explore innovative solutions that can enhance the lives of individuals and foster a more equitable healthcare landscape.”
Frequently Asked Questions
What is the purpose of the federal contract awarded to AIR?
The contract aims to aid in the implementation and monitoring of a program designed to increase access to transformative cell and gene therapy treatments for Medicaid recipients.
What is the CGT Access Model?
The CGT Access Model evaluates a collaborative approach to negotiate and manage outcomes-based agreements to improve health outcomes and access for Medicaid beneficiaries.
Which condition is the initial focus of the CGT Access Model?
The model will initially target Sickle Cell Disease, a genetic blood disorder affecting a significant population in the U.S.
Who are AIR's partners in this initiative?
AIR is partnering with Deloitte and Wally Smith from Virginia Commonwealth University for this project.
What potential benefits does the project foresee?
The project is expected to broaden access to advanced therapies, enhance health equity, and potentially lower long-term healthcare costs.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Bright Green Partners with Benuvia for Raw Material Supply
- Growth Insights for Global Pharma Grade Plastic Packaging Market
- High-Performance Computing Market Growth to USD 92.33 Billion
- Cancer Vaccines Market Growth Forecast and Insights
- Tumour-Infiltrating Lymphocyte Therapy Market Growth Insights
- Performance Coatings Market Growth Opportunities
- Industrial Robotics Market Growth Projections for 2032
- Significant Growth Ahead for Blood Culture Tests Market
- CytoDyn Partners with CRO for Phase II Inflammation Study
- Montana Technologies Reports Strong Q2 Performance and Growth